Streptomycin adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Streptomycin
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Generic name
Class: Aminoglycoside antibacterial

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Drug reports received through 30 Jun 2026. Device reports have a separate cutoff, 30 Sep 2026. Why a report count is not a rate.

Reports on file

From January 2004 to April 2026, FDA received 692 adverse event reports that name Streptomycin. In these reports the drug is a suspect or interacting product.

In the same period, 455 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 8 reports in the 12 months to June 2026 and 22 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 8 (under 0.1%) name Streptomycin. Reports from other health professionals were 68.4% of the reports that name Streptomycin and 19.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Streptomycin is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

The latest update of the FDA data, recorded on 28 Oct 2026, changed no count of this page.

In April to June 2026, FDA received 2 reports that name Streptomycin.
In January to March 2026, FDA received 2.
In April to June 2025, FDA received 5.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 93 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 668 of the 692 reports (96.5%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 93 terms.

Reaction terms in the reports that name Streptomycin, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 692 reports
Drug resistance	124	17.9%
Pyrexiafever	54	7.8%
Drug hypersensitivityan allergic-type reaction (the term names a medicine)	49	7.1%
Drug ineffectivethe medicine did not work as expected	45	6.5%
Paradoxical drug reaction	43	6.2%
Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement	40	5.8%
Nauseafeeling sick	33	4.8%
Tuberculosis	32	4.6%
Pathogen resistance	27	3.9%
Treatment failurethe treatment did not work	26	3.8%
Diarrhoealoose or frequent stools	25	3.6%
Off label useused for a purpose or in a way not on the label	24	3.5%
Rashskin rash	21	3%
Drug-induced liver injury	20	2.9%
Lymphopenia	20	2.9%
Neutropenialow neutrophils, a type of white blood cell	20	2.9%
Hepatitis cholestatic	19	2.7%
Pancreatitisinflammation of the pancreas	19	2.7%
Myalgiamuscle pain	18	2.6%
Hepatotoxicityliver injury	17	2.5%
Hypersensitivityan allergic-type reaction	17	2.5%
Multiple-drug resistance	16	2.3%
Clostridium difficile colitisa bowel infection with C. difficile	15	2.2%
Immune reconstitution inflammatory syndrome	14	2%
Urinary tract infectionbladder or urinary infection	14	2%
Vomitingbeing sick	14	2%
Blood bilirubin increased	13	1.9%
Cough	13	1.9%
Tuberculoma of central nervous system	13	1.9%
Urinary tract inflammation	13	1.9%
Neuropathy peripheralnerve damage in hands or feet	11	1.6%
Product use in unapproved indicationused for a purpose not on the label	11	1.6%
Pulmonary tuberculosis	11	1.6%
Condition aggravatedthe condition being treated got worse	10	1.4%
Jaundiceyellowing of the skin or eyes	10	1.4%
Alanine aminotransferase increasedraised liver enzyme (ALT)	9	1.3%
Conductive deafness	9	1.3%
Decreased appetitereduced appetite	9	1.3%
Disseminated tuberculosis	9	1.3%
Hepatitis	9	1.3%
Immune reconstitution inflammatory syndrome associated tuberculosis	9	1.3%
Lymphadenopathyswollen lymph nodes	9	1.3%
Malaisegeneral feeling of being unwell	9	1.3%
Neurotoxicity	9	1.3%
Aspartate aminotransferase increasedraised liver enzyme (AST)	8	1.2%
Foetal exposure during pregnancythe unborn baby was exposed to the medicine	8	1.2%
Gastrointestinal disorder	8	1.2%
Neuropsychiatric symptoms	8	1.2%
Seizurea fit or convulsion	8	1.2%
Hepatic failureliver failure	7	1%

Download all 93 terms of Streptomycin (CSV)

The counts add to more than 692 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Streptomycin, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Other Serious (Important Medical Events)	Not serious
2004	3	3	1	0	2	0	1	0
2005	3	3	1	0	1	0	1	0
2006	4	4	1	0	1	0	2	0
2007	18	18	0	0	1	0	17	0
2008	2	2	1	0	0	0	1	0
2009	7	7	1	0	1	0	6	0
2010	18	17	3	2	7	1	13	1
2011	17	12	1	1	6	2	9	5
2012	44	39	1	0	11	0	31	5
2013	24	23	4	0	10	2	14	1
2014	30	29	4	0	14	0	17	1
2015	30	25	5	0	0	0	24	5
2016	61	52	17	1	15	1	36	9
2017	44	40	8	0	8	0	33	4
2018	67	63	3	1	6	0	60	4
2019	95	87	11	3	13	0	77	8
2020	67	63	7	4	31	1	51	4
2021	30	25	1	0	8	1	19	5
2022	39	34	4	1	15	1	26	5
2023	45	36	14	4	21	0	29	9
2024	18	15	3	1	7	0	13	3
2025	21	19	1	2	11	0	18	2
2026	5	4	2	2	2	0	4	1

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Streptomycin, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Streptomycin, by the year in which FDA received them
Year	Reports
2004	3
2005	3
2006	4
2007	18
2008	2
2009	10
2010	19
2011	14
2012	49
2013	26
2014	30
2015	31
2016	64
2017	44
2018	76
2019	92
2020	66
2021	31
2022	43
2023	32
2024	16
2025	15
2026	4

Reports that name Streptomycin, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Streptomycin
Age	Reports	Share
Under 2	16	2.3%
2 to 11	58	8.4%
12 to 17	33	4.8%
18 to 44	210	30.3%
45 to 64	128	18.5%
65 to 74	45	6.5%
75 and over	34	4.9%
Age not given	168	24.3%

Sex of the patient in the reports that name Streptomycin
Sex	Reports	Share
Female	249	36%
Male	339	49%
Unknown or not given	104	15%

Type of reporter in the reports that name Streptomycin
Reporter	Reports	Share
Physician	165	23.8%
Pharmacist	10	1.4%
Other health professional	473	68.4%
Lawyer	0	0%
Consumer or non-health professional	21	3%
Not given	23	3.3%

Age and sex are as the report gives them. The reporter is the primary source in the report. 27.5% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Streptomycin record
Indication as recorded (MedDRA)	Reports	Share
Tuberculosis	242	35%
Pulmonary tuberculosis	96	13.9%
Mycobacterium ulcerans infection	33	4.8%
Meningitis tuberculous	27	3.9%
Disseminated tuberculosis	19	2.7%
Brucellosis	5	0.7%

The reporter fills in the indication, and the field is often empty. Each share is of all 692 reports.

Pages near this one

Neomycin sulfate same class
Tobi same class
Neomycin same class
TOBI Podhaler same class
Kitabis Pak same class
TobraDex same class
Strensiq next in the A to Z list
Stresam next in the A to Z list
Strattera next in the A to Z list
Striant next in the A to Z list
Stocrin next in the A to Z list
Stribild next in the A to Z list

These links are for navigation. No count selected them. The class page lists each drug of the class.

Official pages

DailyMed labels for StreptomycinThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Streptomycin: adverse event reports that FDA received. https://reportedreactions.com/drug/streptomycin/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Streptomycin as a suspect or interacting product. The 455 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Streptomycin was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Streptomycin?

No. It is a count of what people reported to FDA: 692 reports from January 2004 to April 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Other health professional (68.4%), physician (23.8%) and consumer or non-health professional (3%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page